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MINIREVIEW
Quorum Sensing in Dimorphic Fungi: Farnesol and Beyond
Kenneth W. Nickerson,1* Audrey L. Atkin,1 and Jacob M. Hornby2
School of Biological Sciences, University of Nebraska, Lincoln, Nebraska 68588-0666,1 and
Division of Natural Sciences, Lewis-Clark State College, Lewiston, Idaho 835012
Production of farnesol by Candida albicans is the first quo-
rum-sensing system discovered in a eukaryote (29). In C. albi-
cans, accumulated farnesol affects both dimorphism (29, 50)
and biofilm formation (62). Fungal dimorphism is defined (64)
as an environmentally controlled reversible interconversion of
morphology, particularly yeast and mycelial morphologies. In-
terest in this shift derives from the dimorphic character of
many fungi that are pathogenic toward plants and animals (64).
Numerous chemical and environmental parameters can shift
the yeast-mycelium dimorphism, including temperature, pH,
glucose levels, nitrogen source, carbon dioxide levels, transi-
tion metals, chelating agents, and inoculum size or initial cell
density (64). Of these, the inoculum size effect is probably the
least well studied. For fungi such as Ceratocystis ulmi (28, 42)
and C. albicans (29), cells develop as budding yeasts when
inoculated at106 cells per ml and as mycelia when inoculated
at 106 cells per ml. We believe the inoculum size effect is a
general phenomenon in dimorphic fungi (Table 1). In keeping
with the precedent established by homoserine lactone-based
signaling in gram-negative bacteria (22), the inoculum size
effect in fungi is also called quorum sensing (29) and the
extracellular cell density-dependent signals are called quorum-
sensing molecules (QSMs). Thus, the chemical identity of
the respective QSMs is of interest. Apart from C. ulmi (28)
and C. albicans (29), it is a “leap of faith” on our part that
the other cell density phenomena listed in Table 1 are me-
diated by QSMs.
The QSM for Candida albicans is E,E-farnesol. Inclusion of
spent medium from C. albicans as part of the fresh growth
medium reduces the percentage of mycelial cells (29). The
active principle is lipophilic and can be extracted with many
organic solvents. The active molecule was identified by gas
chromatography-mass spectrometry as farnesol (1-hydroxy-
3,7,11-trimethyl-2,6,10-dodecatriene; C15H26O; molecular weight,
222.37). Farnesol is a component of many perfumes, including
Chanel No. 5, and its distinctive aroma was used initially in its
purification from C. albicans (29). Farnesol can exist as four
isomers, but only the E,E isomer has QSM activity (72). Far-
nesol prevents mycelial development in both growth morphol-
ogy and differentiation assays. The differentiation assay can be
varied by using three common chemical triggers for germ tube
formation: L-proline, N-acetylglucosamine, and serum. In all
cases, farnesol prevented the yeast-to-mycelium conversion,
resulting in actively budding yeasts without otherwise altering
cellular growth rates, even at concentrations up to 300 M (29,
62). Our early work was done with C. albicans strain A72, a
clinical isolate, and the supernatant from that strain was active
on cells from strains MEN, LGH1095, 10261, SG3314, and
SC5314 (at that time, this strain was mistakenly listed as
SG5314) and vice versa (29). Farnesol is produced at a level
of 0.13 mg/g (dry weight) by two laboratory strains (A72
and CAI-4) and four recent clinical isolates of C. albicans;
only strain 10231 did not produce detectable farnesol (31).
Several technical precautions need to be taken when evalu-
ating the farnesol concentrations needed: (i) only E,E-farnesol
is active; (ii) farnesol oils and stock solutions should be stored
under argon or nitrogen with desiccation; (iii) despite the long-
term stability of E,E-farnesol in water (29), farnesol solutions
in methanol are not as stable; and (iv) the composition of the
growth medium is important (50). For any of five defined
media, 1 to 2 M farnesol sufficed to reduce germ tube for-
mation to 50%. Inclusion of serum increased the amount of
farnesol needed to block yeast-to-mycelium conversion in a
dose-dependent manner. The concentrations needed were
10, 50, 150, and 250 M farnesol with 2, 5, 10, and 20%
serum, respectively (50). These increases probably are due to
the nonspecific lipid binding ability of serum albumin. We
emphasize these experimental considerations because conflict-
ing observations regarding farnesol and its role in quorum
sensing can be attributed to differences in experimental design.
Commitment. Although farnesol blocks the yeast-to-myce-
lium conversion (29, 72), it does not block the elongation of
preexisting hyphae (50, 62). Thus, there is a limited time dur-
ing which cells can respond to farnesol. Resting cells trans-
ferred to hypha-inducing conditions are sensitive to farnesol,
and when the farnesol is added at time zero (Fig. 1), the cells
do not differentiate into hyphae. However, the percentage of
cells committed to hyphal growth increases with time under
hypha-inducing conditions. By60 min (Fig. 1), some cells are
committed to hyphal growth and are therefore insensitive to
farnesol, and by 90 min, almost all cells are committed to
hyphal growth and thus are insensitive to farnesol (54). This
insensitivity to farnesol is likely another manifestation of the
commitment phenomenon (10, 49), in which, once visible germ
tubes have appeared, a shift from hypha-inducing conditions to
bud-inducing conditions no longer causes yeast formation, be-
cause the cells are no longer totipotent (10, 49). The onset of
commitment in C. albicans is rather synchronous and easily
studied (Fig. 1). However, commitment is not permanent (49,
54). Sooner or later, the cells return to being totipotent. In
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liquid culture this return usually happens during stationary
phase (49), and at this point the cells should again become
farnesol sensitive. The timing of this decommitment point re-
mains poorly characterized, in part because it is probably asyn-
chronous. The effect of commitment and decommitment on
farnesol sensitivity will provide insight for interpreting the ef-
fects of farnesol on biofilm formation.
Candida biofilms. The formation of biofilms by C. albicans
and their importance in infection are well documented (15). In
particular, the formation of biofilms on medical equipment,
e.g., catheters, is a serious concern in the progression of infec-
tions caused by C. albicans. This concern is due in part to the
introduction of infective organisms and in part to the greater
resistance to antifungal agents observed for Candida biofilms.
Biofilm formation has been examined by scanning electron
microscopy and confocal laser scanning microscopy. The initial
colonization by yeast cells is followed 3 to 6 h later by germ
tube formation. The adhering yeast cells form a basal layer that
firmly attaches the biofilm to the substrate, while subsequent
germination generates the bulk of the biofilm. After 48 h, a
mature biofilm typically contains yeasts, mycelia, and pseudo-
mycelia (15). Mycelia-only mutants of C. albicans form a rel-
atively loose attachment to the surface, whereas yeast-only
mutants form only the basal layer, and therefore only a very
thin biofilm (15). The presence of cells of multiple morpholo-
gies in biofilms suggests that farnesol has a role in regulating
cellular morphology and therefore in the establishment of ma-
ture biofilms. Ramage et al. (62) found that the effect of far-
nesol on biofilm development was time dependent. Addition of
30 to 300 M farnesol at time zero inhibited biofilm develop-
ment, but addition 1 to 2 h later did not. That is, once hyphal
formation had been initiated, it could no longer be inhibited by
addition of farnesol (62). Interestingly, mature biofilms (24 h)
once more became sensitive to farnesol (62). These results are
consistent with the idea that developing biofilms go through
commitment and decommitment just like planktonic cells in
liquid culture (50). In this model, the release of yeast cells from
mature biofilms would be triggered by the in situ accumulation
of farnesol (62) some time after the decommitment point.
Another line of evidence for involvement of diffusible mol-
ecules, possibly farnesol, in Candida biofilms is that when me-
dium flows across a developing biofilm, e.g., by gentle shaking,
the overall size of the biofilm is significantly larger than if the
liquid is static (15). Based on farnesol’s effects on cellular
morphology and biofilm development, we hypothesize that liq-
uid flowing across a solid surface removes farnesol, leading to
larger biofilms with more cells in the mycelial morphology.
When the rate of flow decreases or when flow is absent, more
farnesol accumulates and, after decommitment, causes new
cells to develop with the yeast morphology. These yeast cells
would diffuse away from the mature biofilm, with the capacity
to start a new biofilm elsewhere.
Anaerobic Candida. Very little research has been done on
the anaerobic growth of C. albicans. This lack is surprising,
since C. albicans infections can spread into the body from the
anaerobic gastrointestinal tract (56). There is a defined liquid
medium for the anaerobic growth of C. albicans (16) based on
the Hungate technique for stringent anaerobes. A distinctive
feature of anaerobic growth was that the cells neither produced
nor responded to exogenous farnesol, even at concentrations
as high as 1.2 mM (16). This difference in farnesol production
between aerobically (31) and anaerobically (16) grown cells
TABLE 1. Fungi reported to exhibit inoculum size effects
Fungus Reference(s) Physiological change Comment
Ceratocystis ulmi 28, 42 Yeast-mycelium dimorphism Dutch elm disease
Candida albicans 29, 57 Yeast-mycelium dimorphism Candidiasis
Histoplasma capsulatum 88 Yeast-mycelium dimorphism Histoplasmosis
Mucor rouxii 2, 18 Yeast-mycelium dimorphism Zygomycete
Aureobasidium pullulans 63 Yeast-mycelium dimorphism Black yeast
Cladosporium werneckii 25 Yeast-mycelium dimorphism
Penicillium isariaeforme 53 Light-induced coremia Photomorphogenic
Trigonopsis variabilis 70 Yeast-triangular transition Triangular cells
Dictyostelium discoideum 13 Germination efficiency Cellular slime mold
Neurospora crassa 68 Galactosamine in cell wall Model system
Neurospora crassa 23 Suppression of cot-1 phenotype
Histoplasma capsulatum 41 (1,3)-Glucan in cell wall
Schizophyllum commune 37 Light-induced growth inhibition in dikaryons Basidiomycete
FIG. 1. The commitment phenomenon. Resting cells transferred
into hypha-inducing conditions are sensitive to farnesol at time zero;
they do not differentiate into hyphae. As the time of farnesol addition
is delayed, there is an increase in insensitivity to farnesol. Emergence
of insensitivity corresponds with the appearance of germ tubes. Sym-
bols in the graph stand for no farnesol added () or farnesol (30 M)
added at time zero (■), 30 min (F), 60 min (Œ), or 90 min (}). GTF,
germ tube formation. The graph was originally published in reference
50.
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shows that farnesol synthesis is regulated. Additionally, anaer-
obic C. albicans cells are highly resistant to amphotericin B and
four azole antifungals, and wild-type C. albicans cells grow
exclusively as mycelia at all temperatures tested: 25, 30, and
37°C (16).
The distinctive physiology of anaerobically grown cells raises
the question, “How anaerobic are the interiors of C. albicans
biofilms?” (16). C. albicans cells are more resistant to flucon-
azole and other antifungal drugs when in biofilms than when
they are planktonic (15, 61). Biofilm cells might be more re-
sistant because they are growing anaerobically. The interiors of
many bacterial biofilms are highly anaerobic, including those
associated with tooth decay and periodontal disease (39).
Anaerobically grown C. albicans does not produce biofilms on
plastic or acrylic surfaces (4), but this observation does not
preclude an aerobically formed biofilm from having an an-
aerobic interior. Finally, physiologically anaerobic cells
would be excellent candidates for “persister” cells, which
remain viable in biofilms following treatment with antimi-
crobial agents (15, 61).
Farnesol synthesis and the sterol pathway. Farnesol is pro-
duced by an alternative pathway from the sterol biosynthetic
intermediate farnesyl pyrophosphate (FPP). FPP is an impor-
tant branch point in lipid metabolism (Fig. 2). Cell extracts of
C. albicans contain an enzymatic activity that can convert
[3H]FPP to [3H]farnesol (30). Saccharomyces cerevisiae con-
tains two relevant pyrophosphate phosphatases, Lpp1p (81)
and Dpp1p (80). Their C. albicans homologs are designated
Dpp2 and Dpp3, respectively. Farnesol production is elevated
in the presence of drugs that block sterol synthesis in fungi. For
0.5 to 1 M zaragozic acid B, fluconazole, clotrimazole, keto-
conazole, and miconazole, farnesol levels were increased 8-,
10-, 45-, 45-, and 44-fold, respectively (30, 31). For both zara-
gozic acid B (30) and fluconazole (31), there was a dose-
dependent relationship between the drug concentration and
the amount of farnesol produced. Zaragozic acid inhibits
squalene synthase (3), while the azoles inhibit lanosterol 14-
demethylase, a key enzyme in ergosterol biosynthesis (Fig. 2).
Production of 0.13 mg farnesol per g (dry weight) is equiv-
alent to a concentration of 2 to 4 M farnesol at a yeast cell
density of 108/ml. We estimated the energetic cost of farnesol
production through the respective carbon flows to farnesol and
ergosterol. If the sterol content of C. albicans is 0.8% (dry
weight) (56), then 1.6% of the FPP is directed to farnesol,
with the remaining 98% going to sterol synthesis. This cal-
culation ignores any additional pathways for carbon flow
through the FPP branch point (Fig. 2).
Industrial production of farnesol. A series of patents have
been issued for the microbial production of prenyl alcohols,
e.g., farnesol and geranylgeraniol (52, 59, 82), for use in the
chemical synthesis of vitamins and hormones. Two general
procedures have been used to achieve farnesol overproduction
by various microbes. In the first approach, genes in the early
mevalonate pathway for FPP synthesis (Fig. 2) are overex-
pressed. For example, overexpression of HMG1 (which en-
codes HMG-coenzyme A [CoA] reductase) in S. cerevisiae
increases farnesol production to 160 mg/liter. In a second ap-
proach, squalene synthase is repressed (48, 59) or inhibited
(21, 52), allowing its substrate, FPP, to accumulate. One
squalene synthase-deficient mutant produced 2.5 g/liter (11.3
mM) of farnesol in 10 days of fed-batch cultivation (48). With
both approaches, prenyl alcohol production depends on the
growth medium and fermentation conditions. Productive me-
dia included (i) high levels of carbohydrate (2 to 7%), (ii) 1 to
3% soybean oil, fish oil, olive oil, or almond oil, and (iii) 0.1 to
0.5% of a nonionic detergent such as NP-40 or Triton X-100
(52). The farnesol yield could be increased more than 1,000
times, to 250 mg/liter, by use of a squalene synthase inhibitor
called SQAD (52) combined with an improved farnesol pro-
duction medium.
The enzymology for farnesol production is common among
fungi. One-third of the Ascomycetes tested had the potential to
produce farnesol or geranylgeraniol (52). In the presence of
SQAD (20 mg/liter), at least 47 fungal species, including 8
Candida species—Candida albicans, Candida utilis, Candida
stellata, Candida solani, Candida intermedia, Candida krusei,
Candida tenuis, and Candida zeylanoides—excrete farnesol
(52). Having such a broad range of microorganisms with the
potential for farnesol production suggests that farnesol excre-
tion proceeds either via simple diffusion or by a very common
transport system. In a rich medium (yeast-malt broth) supple-
mented with 5% glucose, 1% soybean oil, and SQAD (52), C.
albicans excreted 500 M farnesol. Soybean oil and nonionic
FIG. 2. Farnesyl pyrophosphate as a metabolic branch point in
lipid metabolism. Circled and highlighted numbers 1, 2, and 3 indicate
the enzyme targets for zaragozic acid, terbinafine, and fluconazole,
respectively.
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detergents likely promote farnesol production by creating an
external lipid sink. Farnesol has a maximum water solubility of
only 1 to 1.2 mM (38), and an external lipid sink would shift the
equilibrium toward production and excretion of farnesol. Why,
then, do most wild-type strains of C. albicans excrete farnesol
(29, 31), whereas most other fungi do not? Two testable ex-
planations are that C. albicans might have a larger FPP pool
size or that one of the pyrophosphatases in C. albicans (Dpp2
or Dpp3) might have a significantly lower Km for FPP. Reso-
lution of this question awaits measurement of the FPP pool
sizes (77) as well as the availability of purified FPP pyrophos-
phatases.
Farnesol and the fungal physiology of Candida albicans. Far-
nesol was identified as a QSM by its ability to block the yeast-
to-mycelium shift. But what else might it do? Two simple
hypotheses have already been eliminated. The temperature
dependence of polymorphism (64) is not correlated with dis-
continuities in farnesol production, because farnesol is pro-
duced aerobically from 15 to 42°C (29), although it remains
possible that the subcellular localization of farnesol is altered
at different growth temperatures. Also, farnesol production is
not correlated with morphology. For two cases of strictly fila-
mentous growth the farnesol production levels were quite op-
posite. During anaerobic growth the filamentous cells pro-
duced no detectable farnesol (16). In contrast, three obligately
filamentous mutants (6–8) of C. albicans (tup1/tup1, nrg1/
nrg1, and rbf1/rbf1 mutants) produce 6 to 19 times more
farnesol than do wild-type cells (D. Navarathna, A. L. Atkin,
and K. W. Nickerson, unpublished data).
Three other effects of farnesol on C. albicans also have been
reported. Each of these effects requires a much higher concen-
tration of farnesol than that needed to block germ tube for-
mation. First, Hog1, a stress-activated protein kinase, is rapidly
phosphorylated after cells are treated with 100 M farnesol
(76). Second, there is a link between farnesol and the oxidative
stress response in C. albicans (85). Conditioned medium from
a stationary-phase culture protected yeast cells 8- to 10-fold
from H2O2 and superoxide anion-generating agents. Extracel-
lular farnesol is at least partially responsible for this protective
effect (85). It is not known if or how farnesol is altered in the
process of protecting the cells from oxidative stress. Finally,
Jensen et al. (33) isolated 1,111 stable mutants of C. albicans
with altered colony morphology, i.e., they had hairy or wrin-
kled colonies, usually associated with filamentous growth.
Most (96%) of these mutants were farnesol remedial. That is,
when grown on yeast-malt agar plates with 50 M farnesol, the
mutants partially or completely reverted to wild-type colony
morphology (33). The observation that farnesol-remedial mu-
tants are so common (96%) relative to mutants that fail to
respond to farnesol (4%) suggests that farnesol activates/in-
duces a pathway that can override many of the morphogenesis
defects in these mutants (33).
Farnesol and other fungi. Reports of farnesol production or
response by other fungi are rare. The S. cerevisiae erg20 mutant
is defective in FPP synthase (11) and excretes five prenyl al-
cohols (isopentenol, dimethylallyl alcohol, linalool, geraniol,
and farnesol) at a combined concentration of 12.7 mg/liter of
culture. Of these, farnesol was the least common (0.18 mg/
liter). The degradation of HMG-CoA reductase, the rate-lim-
iting enzyme of sterol synthesis (Fig. 3), also is regulated by
farnesol in both S. cerevisiae (73, 74) and Chinese hamster
ovary (47) cells. Low levels of farnesol are produced by many
yeasts used for wine making as a volatile flavor compound (20).
In Neurospora crassa, farnesol has a role in the circadian
rhythm clock that governs conidiation (24). Mutations in three
different genes led to the loss of the circadian rhythm, but the
wild-type rhythms could be restored by 10 to 100 M exoge-
nous farnesol or geraniol. Also in N. crassa, 40 to 70 M
exogenous farnesol restored the wild-type phenotype to cot-1
mutants (O. Yarden, personal communication), which have
abnormal polar extension and branching patterns when grown
at restrictive temperatures (23). The cot-1 gene function is
linked to environmental stress response signaling (23). This
response also is cell density dependent, as cot-1 mutants have
near-wild-type morphology even at restrictive temperatures
when the growth medium is supplemented with spent medium
from high-cell-density cultures. Although farnesol is effective
in suppressing the cot-1 phenotype, there is no evidence that N.
crassa actually makes farnesol or that farnesol is a natural
QSM for N. crassa. The natural QSM for Neurospora remains
to be identified. Also, the suggestion we made above with
regard to our own data on farnesol-remedial mutants of C.
albicans (33), i.e., that farnesol activates/induces a pathway
that can override many of the morphogenesis defects in C.
albicans altered-colony mutants, applies equally well to farne-
sol’s ability to restore wild-type phenotypes to cot-1 (23) and
circadian rhythm (24) mutants of N. crassa. The identity of
such a pathway would be of considerable interest.
Schizophyllum commune is the only basidiomycete listed in
Table 1. Klein et al. (37) described an asymmetric pattern of
dikaryotic growth, which suggested the presence of a light-
stimulated autoinhibitor of growth. This inhibitor may be
schizostatin, a close relative of farnesol. Schizostatin, a C20
trans-1,3-dicarboxylic acid of geranylgeranioic acid, is a novel
squalene synthase inhibitor produced by S. commune (79). As
a squalene synthase inhibitor, schizostatin could cause the ob-
served periodic growth inhibition itself or via the intracellular
accumulation of farnesol.
FIG. 3. Structures of three farnesol analogs. (A) E,E-farnesol;
(B) the 2,3-hydrogenated 4-thia analog (72); (C) the fully hydroge-
nated analog (72); (D) the fluorescent oxime (71). Relative activity
refers to QSM activity, i.e., the ability to block N-acetylglucosamine-
induced germ tube formation (29).
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Antagonism between fungi. Fungal antagonisms have been
documented for at least 65 years (84), and farnesol may play a
role in some of these interactions. For example, in Aspergillus
nidulans, 100 M farnesol triggers apoptosis (69), even though
A. nidulans does not produce detectable extracellular farnesol
(69). The fungus is presumably responding to farnesol pro-
duced by other fungal species. In coculture of A. nidulans with
C. albicans, the number of A. nidulans CFU/ml was reduced
180-fold within 24 h. This inhibitory interaction was elimi-
nated if the coculture contained 1% bovine serum albumin
(69). The dermatophyte Trichophyton rubrum also does not
grow when it is cocultivated with C. albicans or if it is grown on
filtered spent medium from C. albicans (34). Thus, C. albicans
is secreting a metabolic product with fungistatic action. One
hypothesis is that C. albicans uses farnesol to eliminate fungal
competitors within a mammalian host environment. This hy-
pothesis provides a potential explanation as to why pure cul-
tures of C. albicans generally are isolated from clinical lesions
(43). How does C. albicans tolerate relatively high levels of
farnesol (300 M [29, 62]) that are fungistatic (46) or fun-
gicidal for other fungi (69)? This question becomes even more
interesting in light of the fact that some S. cerevisiae strains can
be genetically modified to produce high levels of farnesol (11,
48, 52).
The 3-oxo-C12 homoserine lactone QSM from the bacterium
Pseudomonas aeruginosa has enough structural similarity to
farnesol that at high concentrations (200 M) it can mimic
farnesol’s action and prevent the yeast-to-mycelium shift by C.
albicans (27). Interestingly, the signal cross talk between C.
albicans and P. aeruginosa goes both ways, as evidenced by the
fact that 10 to 25 M farnesol lowers the production of four
homoserine lactones (C6 to C12) by P. aeruginosa by 10-fold
each, which in turn reduces pyocyanin production by those P.
aeruginosa cells (J. Robinson, personal communication).
Farnesol analogs. One strategy for studying farnesol recep-
tors is to develop farnesol analogs. Shchepin et al. (72) exam-
ined 2 natural and 38 synthetic farnesol analogs (Fig. 3) and
found that 22 of the 40 analogs had QSM activity as measured
by their ability to reduce germ tube formation by 50%. Even
the most active of the analogs tested (Fig. 3B), however, had
only 7.3% of the activity of E,E-farnesol. Farnesoic acid, which
also is reported to be a QSM for C. albicans (58), had only
3.2% of the activity of E,E-farnesol (72). Note, however that C.
albicans strain 10231 was used in the study in which farnesoic
acid was identified as a QSM. This strain of C. albicans is the
only strain of this yeast that we know of that does not produce
farnesol (31).
QSM activity is quite sensitive to structural changes. The
10,11-epoxide is 58-fold less active than E,E-farnesol, while the
2,3-epoxide is 260-fold less active. Air oxidation causes epoxide
formation, so these dramatic decreases in QSM activity for the
epoxides are consistent with the susceptibility of farnesol to air
oxidation. Similarly, the 3-methyl side chain is important; in
the 4-thia series, removal of the 3-methyl group reduced ac-
tivity 5-fold, while replacement of the 3-methyl with the bulkier
3-ethyl reduced activity 16-fold (72). Based on these structure-
activity relationships, a direct effect of farnesol on membrane
fluidity can be ruled out and the existence of a highly specific
farnesol receptor inferred.
Fluorescent farnesols. The structural constraints identified
in the analog studies means that simply attaching a fluorescent
chromophore to farnesol is unlikely to be effective. Instead, we
designed an analog with two additional double bonds in the
farnesol backbone, making five conjugated double bonds while
preserving the approximate length, cross section, and hydro-
phobicity of farnesol (71). This fluorescent farnesol had an
excitation maximum of 360 nm and an emission maximum of
465 nm. The corresponding oxime (Fig. 3D) with six conju-
gated double bonds has an excitation maximum of 382 nm and
an emission maximum of 530 nm (71). The oxime avoids the
autofluorescence common in many fungi and extends the ex-
citation range beyond 400 nm, an important feature for con-
focal microscopy. These designs parallel those for the study of
parinaric acid, a naturally fluorescent fatty acid with four con-
jugated double bonds (75). Both the fluorescent farnesol and
its oxime had stronger QSM activity (71) than any of the other
analogs we examined (72). The existence of a farnesol binding
protein/receptor (72) as well as its location can be studied with
fluorescent farnesol analogs (71).
Pathogenicity and therapeutic potential. Cell density regu-
lation of morphology in the dimorphic fungi is important be-
cause many of these fungi are plant or animal pathogens (Ta-
ble 1), and the ability to switch from one cellular morphology
to another is associated with pathogenicity. This hypothesis is
consistent with the roles of each morphological type during an
infection. Yeast cells usually are involved in the initial infection
and in dispersal or dissemination through the vascular system,
whether in an animal or in a plant. On the other hand, mycelia
are invasive forms that can penetrate host tissues. Morphology
changes are accompanied by changes in cell surface antigens
that enable the pathogen to effectively elude the host immune
response (65). Dermatophytic fungi may be limited because
they cannot switch morphologies under host physiological con-
ditions and therefore cannot cause deep-seated infections (67).
The correlation between dimorphism and pathogenicity sug-
gests that interfering with the morphological switch could be
an attractive method for controlling pathogenicity. Manipulat-
ing dimorphism could force an opportunistic pathogen to exist
only in a form that should not damage the host. Many studies
of farnesol production and localization have been done exclu-
sively in vitro (29–31, 55, 62, 85). Since fungal membranes
appear to serve as a sink for farnesol, we expect that host
tissues would behave similarly and that farnesol dynamics in
vivo would differ accordingly. The effect of host tissues on
Candida’s response to farnesol remains to be evaluated.
An early hypothesis was that in a mouse model of candidi-
asis, exogenous farnesol would block hyphal growth and thus
prevent infection and mortality in the subjects. However, mice
treated with farnesol (intraperitoneally, intravenously, or
orally) died significantly faster than did untreated mice (D.
Navarathna and K. W. Nickerson, unpublished data). Mice
also were challenged with C. albicans that had been treated
with subinhibitory doses of fluconazole to increase farnesol
production (31). The extracellular, membrane bound, and in-
tracellular farnesol concentrations of C. albicans cells pre-
treated with 1.0 M fluconazole were 12, 2, and 6 times those
of untreated cells, respectively (55). Mice administered C. al-
bicans pretreated with 0.5 to 1.0 M fluconazole died 2.5 days
earlier and had four-times-higher mortality rates than did mice
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given untreated C. albicans. Thus, the fluconazole-pretreated
cells were 4.2 to 8.5 times more lethal (P  0.001) than un-
treated cells (55). One, but certainly not the only, explanation
for this enhanced pathogenicity is that excreted farnesol acts as
a QSM in vitro but as a virulence factor in vivo when a viru-
lence factor is defined as something produced by the organism
to enhance pathogenicity (1). Farnesol is not an innocuous
molecule and may influence mammalian cells in several ways,
including blocking calcium channels, triggering apoptosis, tar-
geting HMG-CoA reductase (Fig. 2) for degradation, and stim-
ulating cell differentiation (17).
Our studies have focused strictly on intravenously inoculated
C. albicans cells. Maintaining these cells as yeasts after they
enter the circulatory system should aid their dispersal, making
treatment with farnesol counterproductive (55). However, gas-
trointestinal challenge with C. albicans accompanied by farne-
sol administration might be different, because this route of
exposure requires the dimorphic lifestyle for entry. Use of
farnesol as a preventative therapeutic in this context is still
being analyzed.
Farnesol analogs might also be of interest as antagonists.
Some synthetic farnesol analogs can competitively inhibit the
QSM activity of farnesol (J. M. Hornby and K. W. Nickerson,
unpublished data). For example, the QSM activity of farnesol
was reduced threefold by the simultaneous presence of
equimolar hexahydro (saturated) farnesol (Fig. 3C). Similar
levels of QSM antagonism also were found for alternative
stereoisomers of farnesol. The biologically active (E,E)-farne-
sol is inhibited to a small extent by (Z,Z)-farnesol. The next
step is to analyze C. albicans pathogenesis in a mouse model
with and without the addition of these competitive farnesol
analogs.
The effect of farnesol on morphogenic signaling pathways.
The ability of C. albicans to change morphological forms from
unicellular budding yeasts to hyphae and pseudohyphae is con-
trolled largely by changes in transcription (83) and can be
induced by various environmental conditions. These environ-
mental conditions are transduced into a change in morphology
via a network of signal transduction pathways whose activity is
ultimately coordinated by transcription regulators (Fig. 4) (re-
viewed in references 14, 45, 78, and 86). Components of the
CEK1 mitogen-activated protein kinase pathway, the Ras/cy-
clic AMP-dependent pathway, the calcium signaling pathway,
the Rim101-independent pathway, and two-component signal
transduction pathways all have been implicated in filamenta-
tion. These pathways are to some degree specialized, since they
respond to different environmental inducers. Farnesol blocks
filament development induced by environmental signals for
most, if not all, of the signaling pathways that activate filament
development. Thus, farnesol could act to specifically block
each of the morphogenic signaling pathways or could act at a
common control point in morphogenesis.
There are at least two negative regulators of the yeast-to-
hypha and yeast-to-pseudohypha morphological changes in C.
albicans: the Tup1-containing Tup1/Rfg1 and Tup1/Nrg1 com-
plexes and Rbf1. The Tup1/Rfg1 and Tup1/Nrg1 complexes
are transcription repressors. Activation of these complexes re-
presses filament-specific gene expression (5, 7, 35, 51). In the
absence of TUP1, RFG1, or NRG1, C. albicans CAI-4 cells are
filamentous, without yeast-to-hypha induction (6, 8, 35, 51).
The role of Rbf1 (RPG-box-binding factor) is less clear. This
DNA-binding protein binds to the S. cerevisiae RPG box in
vitro and the telomeric repeat sequence of C. albicans (32).
Repression of filament-specific gene expression is a common
control point in morphogenesis (78, 86).
Farnesol increases expression of TUP1 but not that of NRG1
or RFG1 (9). In the presence of farnesol, TUP1 mRNA levels
doubled within 40 min of N-acetylglucosamine stimulation of
germ tube formation (B. Kebaara, A. L. Atkin, and K. W.
Nickerson, unpublished data). This increase coincides with the
time by which cells normally become committed to filament
formation and beyond which exogenous farnesol no longer
blocks germ tube formation (50). Farnesol also prevents in-
duction of the Tup1-regulated, filament-specific genes HWP1,
RBT1, CPH1, and HST7 (19, 62, 66). Cph1 and Hst7 are
essential components in the CEK1 mitogen-activated protein
kinase pathway, one of the signal transduction pathways that
regulate morphogenesis, and Cph1 is a transcription activator
of filament-specific genes. Thus, the down-regulation of CPH1,
HST7, and GAP1 (a gene regulated by Cph1) observed by Sato
et al. (66) is consistent with a secondary effect of farnesol on
TUP1.
A two-component signal transduction pathway also may be
involved in response to farnesol. Candida has three histidine
kinases. Mutants lacking these kinases either do not produce
hyphae (chk1-null mutants) or produce only a limited number
of hyphae at the peripheries of colonies (nik1- and sln1-null
mutants) on serum agar (87). However, the same null mutants
form hyphae on M199 (pH 7.5) at 37°C. The addition of far-
nesol blocks hyphal formation by wild-type cells and by nik1-
and sln1-null mutants but not by chk1-null mutants (40). Thus,
Chk1 is important for inhibition of hyphal development by
farnesol. It is not known if Chk1 is directly involved in the
FIG. 4. Abbreviated scheme showing positive and negative regula-
tors of hypha-specific gene (HSG) expression.
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response to farnesol or if it is a negative regulator of a hyphal
developmental pathway that is unresponsive to farnesol. CHK1
also is regulated by Tup1 (36).
Effect of farnesol on global gene expression. The effect of
farnesol on global gene expression during resumption of
growth following stationary phase (19) and in developing bio-
films (9) has been examined. Consistent with the observation
that farnesol affects expression of Tup1 and Cph1, the pres-
ence of farnesol influenced gene expression. Farnesol had a
similar effect on only 26 genes, but in both studies there were
changes in equivalent functional categories including iron
transport, cell wall synthesis, drug resistance, and progression
through the cell cycle. The differences in specific gene expres-
sion patterns reported from different laboratories probably
reflect differences in growth conditions and in the time when
cells were collected for RNA extraction.
Enjalbert and Whiteway (19) analyzed the transcriptional
reprogramming caused by the resumption of growth in the
presence and absence of farnesol. Their strategy allowed them
to distinguish gene expression changes due to farnesol-induced
morphological differences, e.g., differences in cell adhesion,
cell wall formation, chromatin, DNA replication, and the cell
cycle, from those due to the continued presence of farnesol,
e.g., drug response and fatty acid oxidation. These data (19)
must be analyzed with some caution, however, since the pres-
ence of farnesol did not completely suppress hyphal formation
under the conditions used.
Cao et al. (9) allowed the cells to adhere, then added far-
nesol, and collected cells 24 h after farnesol addition for RNA
and microarray analysis. Twenty-four hours is the time re-
quired to form a mature biofilm in the absence of farnesol.
There are three caveats regarding the interpretation of the Cao
et al. (9) data. First, mRNA was measured at only a single time
point, 24 h after the addition of farnesol. Second, cells that
have adhered are a mixed population of yeasts, hyphae, and
pseudohyphae. Finally, the level of farnesol used was 40-fold
higher than that required for a response by the responsive
cells, and at high levels, lipophilic molecules such as farnesol
can trigger nonspecific changes. These points are significant
because Cao et al. (9) detected only stable long-term changes
in gene expression from a mixed population of cells, some of
which are insensitive to farnesol. Additional microarray studies
are needed to examine the effect of farnesol on transcription at
the time of morphological commitment, using minimum far-
nesol concentrations on cultures that are100% responsive to
farnesol.
Other QSMs from C. albicans. The levels of E,E-farnesol
made by C. albicans (31) can account for all of the QSM
activity present in C. albicans cell-free supernatants (72). How-
ever, these corresponding numbers do not prove that farnesol
is the only QSM made. More than 20 years ago, Hazen and
Cutler (26) described a morphogenic autoregulatory substance
(MARS) isolated from C. albicans. Both farnesol and MARS
are extracellular molecules that suppress the yeast-to-hypha
transition. However, MARS differs from farnesol in that it has
a UV maximum at 270 nm, has a nitrogen-containing ring
system, reacts with ninhydrin to form a yellow color, must be
bioassayed within 2 days, is inactivated at pHs of9.0 or4.5,
and has no aroma. The chemical structure of MARS has not
yet been identified.
Oh et al. (58) identified E,E-farnesoic acid as the QSM for
C. albicans, but we found that farnesoic acid has only 3.3% of
the QSM activity of farnesol (72). Significantly, Oh et al. (58)
used C. albicans strain 10231, which is the only strain of C.
albicans known not to produce farnesol (31). Chen et al. (12)
identified tyrosol as a QSM produced by C. albicans strain
SC5314. They provided evidence that this molecule stimulated
the yeast-to-hypha conversion rather than inhibiting it as far-
nesol does. However, the exact function of tyrosol remains
unclear. When farnesol and tyrosol are present in direct com-
petition, tyrosol does not alter the QSM activity of farnesol,
even when the tyrosol is present at a 16-fold molar excess (S.
Ghosh and K. W. Nickerson, unpublished data). Similarly,
tyrosol did not contribute to the protection from oxidative
stress provided by stationary-phase supernatants of C. albicans
(85) or to the stimulation by C. albicans of homoserine lactone
production by P. aeruginosa (J. Robinson, personal communi-
cation). C. albicans also has been reported to secrete phenethyl
alcohol and tryptophol (44), and presumably the three aro-
matic alcohols have a common biosynthetic origin. A pathway
whereby the respective aromatic amino acids undergo
transamination followed by decarboxylation seems likely.
Final thoughts. Farnesol’s action as a QSM for C. albicans
appears to be highly specific. Farnesol does not affect the
morphology of either C. ulmi or Penicillium isariaeforme (28),
and it is not the cell density modulator (41) of (1,3)-glucan
synthesis in Histoplasma capsulatum (W. E. Goldman, personal
communication). However, the mechanism for this specificity
is not yet clear. It could be resolved by identifying the farnesol
binding proteins from C. albicans along with their cellular
localization.
Are the many effects of farnesol on C. albicans manifesta-
tions of one or more underlying phenomena? We think that
blockage of the yeast-to-mycelium shift at 1 to 2 M farnesol
(50, 72) is quite distinct from the reversible shift in colony
morphology at 50 to 100 M farnesol (33) and from other
physiological changes requiring 100 M farnesol (23, 24, 76,
85). Additionally, it is not clear how C. albicans balances using
farnesol as a QSM to regulate its own morphology (29), as a
potential virulence factor during pathogenesis (55), and as a
trigger for apoptosis in other fungi (69). In particular, how
does C. albicans tolerate high levels of farnesol and avoid
apoptosis when it is itself susceptible to apoptosis triggered by
environmental stresses (60)? Based on microarray analysis (9),
C. albicans perceives farnesol as an environmental stress, but
somehow that stress signal is either sidetracked or sidestepped.
The numerous and complex effects of farnesol on C. albicans
suggest that much remains to be done to understand the mul-
titude of changes this molecule can induce in this very impor-
tant yeast.
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